Evidence map›Paper›PMID 37166759›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023

Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021.

Carolin Stoltidis-Claus, Kerstin Daniela Rosenberger, Falitsa Mandraka, Xenia Quante, Jörg Gielen, Dennis Hoffmann, Hilmar Wisplinghoff, Nathalie Jazmati

Erratum issuedAbstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Rising antimicrobial resistance in urinary tract infections in Türkiye: an urgent need for update on regional treatment strategies and for enhanced antimicrobial stewardship efforts.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Lessons from an 11-year retrospective cohort study ofIranian journal of microbiology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Letter to the editor: Antimicrobial resistance data and treatment guidelines - challenges in the context of urine samples and mecillinam testing.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Carolin Stoltidis-ClausWisplinghoff laboratories, Cologne, Germany.
Kerstin Daniela RosenbergerInstitute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Falitsa MandrakaWisplinghoff laboratories, Cologne, Germany.
Xenia QuanteWisplinghoff laboratories, Cologne, Germany.
Jörg GielenInstitute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
Dennis HoffmannWisplinghoff laboratories, Cologne, Germany.
Hilmar WisplinghoffWisplinghoff laboratories, Cologne, Germany.
Nathalie JazmatiWisplinghoff laboratories, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionEmpirical therapy for the treatment of urinary tract infections should be tailored to the current distribution and susceptibility of potential pathogens to ensure optimal treatment.AimWe aimed to provide an up-to-date overview of the epidemiology and susceptibility of Enterobacterales isolated from urine in Germany.MethodsWe retrospectively analysed antimicrobial susceptibility data from 201,152 urine specimens collected between January 2016 and June 2021 from in- and outpatients. Multiple logistic regression analysis was used to evaluate the association between year of investigation and antibiotic resistance, adjusted for age, sex and species subgroup. Subgroup analyses were performed for midstream urine samples obtained from (i) female outpatients aged 15 to 50 years, (ii) female outpatients older than 50 years and (iii) male outpatients.ResultsResistance rates of less than 20% were observed for nitroxoline (3.9%), fosfomycin (4.6%), nitrofurantoin (11.7%), cefuroxime (13.5%) and ciprofloxacin (14.2%). Resistance to trimethoprim/sulfamethoxazole (SXT) (20.1%), amoxicillin-clavulanic acid (20.5%), trimethoprim (24.2%), pivmecillinam (29.9%) and ampicillin (53.7%) was considerably higher. In the subgroup of outpatient women aged 15-50 years, resistance rates were generally lower. Resistance rates of all antibiotics decreased from 2016 to 2021. Multiple logistic regression revealed the lowest adjusted odds ratio (ORadj) of 0.838 (95% confidence interval (CI): 0.819-0.858; p < 0.001) for pivmecillinam and the highest ORadj of 0.989 (95% CI: 0.972-1.007; p = 0.226) for nitrofurantoin.ConclusionsResistance has generally decreased over the past years, independent of sex, age and causative pathogen. Our data provide an important basis for empirical antibiotic recommendations in various settings and patient collectives.

Indexed as

Amdinocillin PivoxilEscherichia coli InfectionsUrinary Tract InfectionsAnti-Bacterial AgentsDrug Resistance, BacterialEscherichia coliFemaleGermanyHumansMaleMicrobial Sensitivity TestsNitrofurantoinRetrospective StudiesTrimethoprim, Sulfamethoxazole Drug CombinationAmdinocillin PivoxilAnti-Bacterial AgentsNitrofurantoinTrimethoprim, Sulfamethoxazole Drug CombinationAMRASTEnterobacteralesGermanyIDresistancesusceptibilityurineUTI

Identifiers

PMID37166759
PMCPMC10176829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.